Last reviewed · How we verify

NCT04488406: GeneGO

Genetics and Epigenetics of Graves' Orbitopathy

Completed Last updated 28 July 2020
What this trial tests

trial testing No Intervention in Graves Ophthalmopathy in 12 participants. Completed in 31 March 2020.

Timeline
1 January 2020
Primary endpoint
31 March 2020
31 March 2020

Quick facts

Lead sponsorUniversity of Pisa
StatusCompleted
Study typeOBSERVATIONAL
Enrollment12
Start date1 January 2020
Primary completion31 March 2020
Estimated completion31 March 2020
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

University of Pisa

Who can join

Adults 18 to 85, any sex, with Graves Ophthalmopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Graves' orbitopathy (GO) is an autoimmune disease persisting when immunosuppression is achieved. Orbital fibroblasts from GO patients display peculiar phenotypes even if not exposed to autoimmunity, possibly reflecting genetic or epigenetic mechanisms, to be investigated here. Primary cultures of orbital fibroblasts from GO and control patients will be established. Cell proliferation, release of hyaluronic acid (HA) and HA synthases (HAS) will be measured. Next Generation Sequencing and gene expression analysis of the whole genome will be performed, as well as global DNA methylation assay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

Other recruiting trials for Graves Ophthalmopathy

Currently open trials in the same condition.

Other University of Pisa trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04488406.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing